Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2)
| Autor: | Mario Cazzola, William R. Fairweather, William W. Howard, Marc F. Goldstein, Frank Lloyd Dini, Luigino Calzetta, Nicola A. Hanania |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Placebo Double blind 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Theophylline Forced Expiratory Volume Internal medicine Humans Medicine Asthmatic patient Albuterol Pharmacology (medical) In patient 030212 general & internal medicine Randomized Controlled Trials as Topic Doxofylline Asthma business.industry Biochemistry (medical) medicine.disease Bronchodilator Agents Pooled analysis 030228 respiratory system chemistry Female business medicine.drug |
| Zdroj: | Pulmonary Pharmacology & Therapeutics. 53:20-26 |
| ISSN: | 1094-5539 |
| DOI: | 10.1016/j.pupt.2018.09.007 |
| Popis: | This pooled analysis of double-blind, randomized, placebo-controlled trials aimed to investigate the impact of DOxofylline compaRed tO THEOphylline (DOROTHEO 1 and DOROTHEO 2 studies) on functional and clinical outcomes in asthma. Asthmatic patients ≥16 years of age with forced expiratory volume in 1 s (FEV1) ≥50% and 0.05) increase the risk of AEs compared to placebo, conversely in patients treated with theophylline 250 mg the risk of AEs was significantly (p < 0.05) greater than in those that received placebo. We conclude that doxofylline seems to offer a promising alternative to theophylline with a superior efficacy/safety profile in the management of patients with asthma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect